Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim
about
Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemiaHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicRational Combinations of Targeted Agents in AMLLBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling.Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.Bortezomib and belinostat inhibit renal cancer growth synergistically by causing ubiquitinated protein accumulation and endoplasmic reticulum stress.Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathwayThe NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.Epigenetic roles of MLL oncoproteins are dependent on NF-κBTherapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.Understanding the role of miRNA in regulating NF-κB in blood cancer.Romidepsin for the treatment of non-Hodgkin's lymphoma.Mechanisms of resistance to apoptosis in the human acute promyelocytic leukemia cell line NB4.The role of the proteasome in AML.A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors.Targeting the regulatory machinery of BIM for cancer therapy.Simultaneous NF-κB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo.A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin.Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug Effectiveness from Cancer Genomic Signature.Histone deacetylase 6 in cancer
P2860
Q33828073-43ADB1E3-BC1E-4101-B5C5-D6668CACFCF9Q33983255-8A4AD77B-8EC8-47CB-965D-6D8E22BDD2C3Q34575453-0983F58A-F412-49C2-8677-F46B7C759B9CQ34817365-27369304-5871-48C2-8285-F3ADF6227BCFQ35750491-C1354765-7BCB-48D1-887F-274D0D673498Q35782878-BA4EB30B-E923-49CC-BD0D-11182D7E3FBDQ35879576-8290346E-F895-4FBB-A6B2-EF566DEC25DFQ36141927-E11DC415-4AC2-4D9F-867F-762F57619B0FQ36321535-C491743A-318A-4E2A-B32D-A2097DA5C19EQ36412841-63F4FD08-B67B-4DE5-81CA-2CEBC66945CAQ36876973-4DF28719-40DF-40E8-B711-9B16C4F667C3Q36927012-EE3DC0E8-1B52-415E-B73E-A413777CE6E9Q37277091-9585194E-751E-451A-BCB3-6DB730B4E535Q37301751-463EC2B2-EF72-4972-8AA5-D1A724F88894Q37972140-0E765083-D656-4432-B16A-4466D10613ADQ38455740-1EC2C0E1-CB1A-4796-85F0-C50870715411Q38947220-342FA181-B67E-4FD3-8E73-31CA90B95116Q39027087-02C89FDD-64A2-40A9-BA2E-645CF3B85858Q39287526-4C1FF3AA-C53B-4462-A102-882F46E22D80Q39575518-AA5C6EAB-03C2-4830-A51D-FF67B4534F2BQ42647696-9D4DEEF1-EAE2-4B3A-A63E-BB787E6B8E45Q47637390-7BC94674-8D4F-428F-91A2-AC0688FDC597Q54472192-448E022F-56B4-4AAB-A489-6AE330B95BEDQ55216429-D5B7C649-4CC0-4496-AF57-239E63432FEAQ58768571-80761C08-CA96-4978-ABD5-950C672298F2
P2860
Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Bortezomib interacts synergist ...... perturbations in NF-κB and Bim
@ast
Bortezomib interacts synergist ...... perturbations in NF-κB and Bim
@en
type
label
Bortezomib interacts synergist ...... perturbations in NF-κB and Bim
@ast
Bortezomib interacts synergist ...... perturbations in NF-κB and Bim
@en
prefLabel
Bortezomib interacts synergist ...... perturbations in NF-κB and Bim
@ast
Bortezomib interacts synergist ...... perturbations in NF-κB and Bim
@en
P2093
P2860
P1476
Bortezomib interacts synergist ...... perturbations in NF-κB and Bim
@en
P2093
Lora B Kramer
Shuang Chen
Steven Grant
Xin-Yan Pei
P2860
P304
P356
10.1111/J.1365-2141.2011.08591.X
P407
P50
P577
2011-03-06T00:00:00Z